Transformative biotechnologies Grant the hope of life
TCR-T Cell Therapy
TCR Bispecific Antibody Drugs
-
Targeting＞90% of the proteome (including intracellular proteins)
-
Superior homing ability into solid tumor tissue
-
TCR-T therapies demonstrated remarkable efficacy in solid tumors
-
TCR-T therapies take advantage of natural TCR signaling resulting higher antigen sensitivity, mild CRS response and better safety profile
-
Targeting＞90% of the proteome (including intracellular proteins)
-
Clinical trials have shown encouraging efficacy with bispecific TCR
-
Mild CRS response and better safety profile
-
Better Availability, Affordability, and Accessibility help to address a wide range of cancer indications and first-line treatments